ARGX heads into the first week of August with a jarring short-score spike doing most of the talking — the stock is down 12% over the past month, borrow conditions remain completely unthreatening, and analyst data is too stale to lean on.
The most striking data point this week is the ORTEX short score, which nearly doubled overnight. It jumped from 25.4 on August 3 to 43.1 on August 4 — a sharp single-session move after a period of stability in the mid-25s. That said, the score had previously been running in the low 40s through most of late July before dropping off on July 28, so this latest reading is a return to recent norms rather than a genuine new high. The combined score mirrors this at 43.0. The short-score rank sits at the 48th percentile across the universe — middling, not alarming.
The lending market flatly contradicts any bearish read from the score. Borrow availability is essentially unlimited — availability registers above 9,999% of shares borrowed, meaning there are vastly more shares in the lending pool than are currently shorted. With over 11 million shares available to borrow and utilization at just 0.63% of the float, there is no squeeze pressure and no meaningful demand from short sellers to build positions. Cost to borrow at 0.66% is near the lowest level in the 30-day window and has drifted lower on the month. The days-to-cover rank of 79th percentile reflects a stock where shorts could exit quickly if needed. Positioning looks loose rather than crowded.
Institutional ownership tells a more engaged story on the long side. FMR (Fidelity) and BlackRock are the two largest holders at 7.9% and 7.4% of shares respectively, both adding modestly in the quarter to June. Capital Research and Management made the most notable move in the period, adding 350,000 shares to reach a 3.6% stake — the largest quarterly addition in the top-15. Norges Bank Investment Management also added 38,000 shares as recently as July 6. The only meaningful open-market sell in the insider data is the Non-Executive Vice Chairman, who sold 4,600 shares at €783.71 on July 28 — a $4.1 million transaction, though the trade significance score is low at 2 out of 10, suggesting it registers as routine rather than a bearish signal.
The July 23 earnings print is the most recent catalyst on record. The stock gained 6.1% on the day but gave back some of that over the following week, finishing the five-day window down 1.6%. That one-day pop following the Q2 release contrasts with the subsequent monthly decay — the stock has shed 12.4% over the past month from what were higher levels. Next earnings are scheduled for October 22, leaving a roughly 11-week window before another fundamental catalyst. Factor scores offer a mixed read: EPS surprise ranks at the 82nd percentile, reflecting a strong track record of beating estimates, and EPS momentum over 30 and 90 days sits at 74 and 70 respectively. Forward EPS growth year-on-year is weaker, ranking at just the 32nd percentile — suggesting the company beats on reported numbers but faces more modest expectations for incremental acceleration. The P/E multiple has compressed from roughly 30.9x a month ago to 26.7x now, tracking the price decline rather than any earnings revision.
Among correlated peers, ABBV had the roughest week, falling 7.4% — a sharper move than argenx's 5.7% decline. GMAB and BIOA B lost 1.6% and 2.3% respectively, while SANION bucked the sector and gained 3.0%. The breadth of weakness across biotech and rare-disease names suggests sector headwinds rather than stock-specific pressure as the primary driver of argenx's monthly drift. The next key watch point is whether the short-score elevation persists through the week, and whether the institutional flows into the October earnings window show any change in conviction from the active managers who have been steady buyers.
See the live data behind this article on ORTEX.
Open ARGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
